Literature DB >> 24260099

Association between the telomerase reverse transcriptase (TERT) rs2736098 polymorphism and cancer risk: evidence from a case-control study of non-small-cell lung cancer and a meta-analysis.

Haijian Wu1, Naian Qiao, Yang Wang, Man Jiang, Shikun Wang, Cuihong Wang, Likuan Hu.   

Abstract

BACKGROUND: A common genetic variant, telomerase reverse transcriptase (TERT) rs2736098, was recently reported to be associated with lung cancer risk in Caucasians. In addition, many studies have investigated the role of this polymorphism in the etiology of cancer of various organs. Nevertheless, the results of related case-control studies remain inconsistent.
METHODS: We hypothesized that the genetic risk variant identified in Caucasians may potentially influence the susceptibility to lung cancer in the Chinese population. To test this hypothesis, a case-control study including 539 non-small-cell lung cancer (NSCLC) cases and 627 cancer-free controls was conducted. Furthermore, to investigate the association between rs2736098 and cancer risk, a meta-analysis based on previously published studies and our case-control study was also performed.
RESULTS: Multivariate logistic regression demonstrated that individuals carrying the A allele or the AA genotype exhibited a significantly elevated risk of NSCLC compared with those carrying the G allele or GG genotype (A vs. G: OR = 1.21, 95% CI = 1.02-1.43, P = 0.028; AA vs. GG: OR = 1.48, 95% CI = 1.05-2.09, P = 0.025). Additionally, this association was stronger among adenocarcinoma cases (AA vs. GG: OR = 1.67, 95% CI = 1.12-2.50, P = 0.013; A vs. G: OR = 1.28, 95% CI = 1.05-1.57, P = 0.016). In the meta-analysis, a borderline significant association between the rs2736098 polymorphism and overall cancer risk was observed (AA vs. GG: OR = 1.25, 95% CI = 1.07-1.46; AA vs. AG+GG: OR = 1.22, 95% CI = 1.06-1.41; additive model: OR = 1.10, 95% CI = 1.02-1.18), and further stratifications demonstrated a moderately increased risk for lung and bladder cancer, Asian ethnicity and hospital-based studies.
CONCLUSIONS: Our results suggest that the rs2736098 polymorphism may contribute to the risk of lung cancer, especially adenocarcinoma, in the Chinese population. In addition, the current meta-analysis indicates that this genetic variant is only weakly associated with overall cancer risk. However, the rs2736098 polymorphism may affect individual susceptibility to lung and bladder cancer. Further studies are needed to validate our findings.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24260099      PMCID: PMC3834105          DOI: 10.1371/journal.pone.0076372

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Worldwide, lung cancer was the leading cause of cancer deaths in males and the second leading cause of cancer deaths in females in 2008. The geographical and temporal patterns of lung cancer incidence are largely determined by tobacco consumption. Lung cancer rates are increasing in countries such as China and several other countries in Asia and Africa, where the smoking prevalence continues to either increase or show signs of stability [1]. Approximately 80% of the 1.3 billion current smokers worldwide live in low- and middle-income countries, with over 300 million in China alone [2]. Non-small-cell lung cancer (NSCLC), which includes two main histological types, squamous cell carcinoma (SQC) and adenocarcinoma (ADC), accounts for nearly 85% of all lung cancer cases. Despite considerable therapeutic progress, the prognosis of NSCLC patients remains poor [3]. The development of lung cancer appears to be the result of a complex interaction between environmental exposures and genetic factors. Recently, independent genome-wide association studies (GWAS) [4]–[9] have demonstrated that single nucleotide polymorphisms (SNPs) in three separate chromosomal regions (5p15, 6p21, and 15q25), which contain genes that regulate nicotinic acetylcholine receptor (nAChR) and telomerase production, are significantly associated with lung cancer risk. 5p15.33, a crucial genomic region for telomere biology, contains two well-known genes: telomerase reverse transcriptase (TERT) and cleft lip and palate trans-membrane 1-like (CLPTM1L). TERT protein is the telomerase catalytic subunit that elongates telomeres and serves as a key regulator of telomerase activity. Telomeres, consisting of TTAGGG repeats that undergo shortening with each cell replication cycle, have long been known to be essential for the preservation of chromosomal integrity [10]. As telomerase and the control of telomere length are intimately linked to the development of many tumor types, scientific attention has focused on the possibility of targeting telomerase and telomere-binding proteins in therapeutic strategies against cancer [11], [12]. Recently, it has been reported that genetic variants at the 5p15.33 locus, which contains the TERT gene (encoding the catalytic subunit of telomerase), are involved in the susceptibility of many tumor types [13], [14]. A common genetic variant, TERT rs2736098, which is located on chromosome 5p15.33, was recently identified as a susceptibility locus for lung cancer in a combined analysis of Icelandic and European sample sets [15]. More recently, a Korean population study of 720 lung cancer patients and 720 healthy controls revealed that the TERT A variant genotype is associated with a significantly increased risk of lung cancer [16]. Given the relevance of this genomic region (5p15.33) to tumor biology and the need to verify these associations in diverse populations with different ancestries, we hypothesized that the risk genetic variant (rs2736098) identified by previous studies of Caucasian and Korean populations may potentially influence the susceptibility to lung cancer in the Chinese Han population. To test this hypothesis, we genotyped the SNP rs2736098 and analyzed its association with the risk of lung cancer in a case–control study of 539 NSCLC cases and 627 cancer-free controls matched by age and gender in a Chinese Han population. Furthermore, many studies have investigated the role of this polymorphism in the etiology of cancer of various organs, including the bladder, liver, and breast [17]–[27]. However, the results of related published case-control studies remain conflicting rather than conclusive. Therefore, to further explore the association between the TERT rs2736098 polymorphism and cancer risk, a meta-analysis based on previously published studies and our case-control study was also performed.

Materials and Methods

Case-control study

Study population

To exclude the possible effects of ethnicity, all subjects in this study were genetically unrelated ethnic Han Chinese. The cases included 539 newly diagnosed NSCLC patients who were admitted to the Qilu Hospital of Shandong University (Jinan, China) between 2010 and 2012. Of these NSCLC patients, 293 patients had adenocarcinomas (ADC) and 246 had squamous cell carcinomas (SQC). Meanwhile, 627 cancer-free controls were selected from the same hospital and were frequency-matched to cases by age and sex. Subjects who were relatives or had histories of malignancy and other major diseases were excluded from this study. In addition, a structured questionnaire was completed for each case and control by a trained interviewer to collect demographic data and other relevant information, including age, sex, and smoking status. Those individuals who smoked <1 cigarette per day and for <1 year were defined as nonsmokers; otherwise, the patients were considered smokers. All participants were given an explanation of the study, and written informed consent was obtained from each participant. This study was conducted under the approval of the Ethics Committees of Qilu Hospital affiliated to Shandong University.

DNA extraction and SNP genotyping

Blood samples were collected from all participants at the time of recruitment. Genomic DNA was extracted from peripheral blood obtained from each participant using the DNA Extraction Kit (Tiangen Biotech (Beijing) Co., Ltd.) according to the manufacturer's protocol. The TERT SNP rs2736098 was genotyped using the TaqMan methodology in 96-well plates and read with the Sequence Detection Software (SDS, version 1.4) on an Applied Biosystems (ABI) 7500 Real-Time PCR System.

Statistical analysis

The Pearson χ2 test was employed to evaluate the differences in the distributions of selected characteristics between the cases and controls. The goodness-of-fit χ2 test was adopted to assess Hardy-Weinberg equilibrium (HWE) in the controls. Multivariate logistic regression analysis was used to estimate odds ratios (ORs) and their 95% confidence intervals (CIs) for the effect of rs2736098 polymorphism on NSCLC risk. In addition, stratified analyses by histological types were further performed to evaluate the role of rs2736098 in NSCLC risk. All statistical tests were two-sided, and statistical significance was accepted as P<0.05.

Meta-analysis

Identification and eligibility of relevant studies

To further investigate the association between the TERT rs2736098 polymorphism and cancer risk, a meta-analysis based on previously published studies and our case-control study was performed. We searched the PubMed and ISI Web of Science databases for all articles on the association between the TERT rs2736098 polymorphism and cancer risk (last search update 5th June 2013). The following search terms were used in isolation and in combination with one another: “telomerase reverse transcriptase or TERT or 5p15.33”, “polymorphism or variant or variation”, and “cancer or carcinoma or tumor”. The search was limited to English language papers and human studies. In addition, we screened the reference lists for all included studies, reviews and meta-analyses. When multiple publications reported on the same or overlapping data, we selected the most recent publication with the most subjects. Studies included in our meta-analysis had to meet the following inclusion criteria: (1) evaluation of the TERT rs2736098 polymorphism and cancer risk; (2) a case-control design; (3) sufficient genotype data for the calculation of odds ratios (OR) with 95% confidence intervals (CIs); and (4) written in English. The major reasons for exclusion of studies included (1) the lack of a control group; (2) duplicates of previous publications; (3) reviews, comments or editorials; and (4) a lack of usable data on genotype frequencies.

Data extraction

Two investigators (Wu H and Wang Y) extracted information from all eligible publications independently according to the inclusion criteria listed above. Disagreements were resolved by discussion until consensus was achieved on every item. In the present study, the following characteristics were collected: the first author's last name, the year of publication, the country of origin, ethnicity, cancer type, the source of the control groups (population- or hospital-based controls), the genotyping method, and the frequencies of genotypes in cases and controls. For studies including subjects of different ethnic groups, genotype frequencies and other information were extracted separately for each ethnic group whenever possible [21]. We first assessed the Hardy-Weinberg equilibrium (HWE) for the controls in each study. The strength of the association between the TERT rs2736098 polymorphism and cancer risk was evaluated by the odds ratios (ORs) with 95% confidence intervals (CIs). The pooled ORs were calculated for homozygote comparison (AA vs. GG), heterozygote comparison (AG vs. GG), the dominant genetic model (AA+AG vs. GG), the recessive genetic model (AA vs. AG+GG), and the additive genetic model (2*AA+AG vs. 2*GG+AG). Stratified analyses were performed by cancer type (if one cancer type contained less than two individual studies, it was combined into the ‘other cancers’ group), ethnicity and source of the controls. The evaluation of the meta-analysis results included an examination of the heterogeneity, an analysis of the sensitivity, and an examination for publication bias. Heterogeneity was checked by the chi-square-based Q-test [28]. If the result of this heterogeneity test was P<0.05, then the pooled ORs were calculated using the random effects model (the DerSimonian and Laird method) [29]. Otherwise, if the result of this heterogeneity test was P>0.05, the fixed-effects model was selected (the Mantel–Haenszel method) [30]. We also used the I statistic to efficiently test for heterogeneity, with I<25%, 25–75% and >75% representing low, moderate and high degrees of inconsistency, respectively [31], [32]. Additionally, sensitivity analyses were performed by omitting each study to reflect the influence of the individual data on the summary ORs. Finally, literature publication bias was estimated using the Begg's funnel plot and Egger's test (P<0.05 was considered a significant publication bias) [33], [34]. All statistical analyses were performed using the STATA software (version 12.0; Stata Corporation, College Station, TX).

Results

Results of the case-control study

Population characteristics

The characteristics of the cases and controls are presented in Table 1. A total of 539 NSCLC cases and 627 cancer-free controls were enrolled in this study. There were no significant differences in the distributions of sex (P = 0.403) and age (P = 0.688) between the case and control groups. Males represented 79.7% of the control group and 77.7% of the case group. Of the 539 NSCLC cases, 293 (54.4%) were adenocarcinomas, and 246 (45.6%) were squamous cell carcinomas. Approximately 51.8% of cases were smokers, compared with 43.1% of controls (P = 0.003).
Table 1

Selected characteristics of non-small-cell lung cancer cases and controls.

CharacteristicsN (%) P *
Cases (n = 539)Controls (n = 627)
Age (years)
≤60278(51.6)316(50.4)0.688
>60261(48.4)311(49.6)
Sex
Male419(77.7)500(79.7)0.403
Female120(22.3)127(20.3)
Smoking status
Ever279(51.8)270(43.1)0.003
Never260(48.2)357(56.9)
Histology
SQC246(45.6)
ADC293(54.4)

Abbreviations: ADC, adenocarcinoma; SQC, squamous cell carcinoma.

P value was calculated by the χ2 test.

Abbreviations: ADC, adenocarcinoma; SQC, squamous cell carcinoma. P value was calculated by the χ2 test.

Association between the TERT rs2736098 polymorphism and NSCLC risk

Data for the genotype frequencies and the association between the TERT rs2736098 polymorphism and NSCLC risk are shown in Table 2. The distribution of genotypes among the control subjects was in accordance with Hardy–Weinberg equilibrium (P = 0.361). The multivariate logistic regression model demonstrated that individuals carrying the A allele or AA genotype exhibited a significantly elevated risk of NSCLC compared with those carrying the G allele or GG genotype, after adjusting for age, gender and smoking status (A vs. G: OR = 1.21, 95% CI = 1.02–1.43, P = 0.028; AA vs. GG: OR = 1.48, 95% CI = 1.05–2.09, P = 0.025).
Table 2

Association between the rs2736098 polymorphism and non-small-cell lung cancer risk in a Chinese Han population.

GenotypesCases (n = 539), N (%)Controlsa (n = 627), N (%)OR (95%CI)b P b
Total
GG205 (38.0)263(41.9)1.00
AG232(43.0)278(44.3)1.09(0.85–1.41)0.501
AA102(18.9)86 (13.7)1.48(1.05–2.09)0.025
AA+AG334/205364/2631.18(0.93–1.50)0.163
A allele1.21(1.02–1.43)0.028
ADC
GG106(36.2)263(41.9)1.00
AG126(43.0)278(44.3)1.13(0.83–1.54)0.450
AA61(20.8)86(13.7)1.67(1.12–2.50)0.013
AA+AG187/106364/2631.25(0.94–1.67)0.132
A allele1.28(1.05–1.57)0.016
SQC
GG99(40.2)263(41.9)1.00
AG106(43.1)278(44.3)1.07(0.77–1.49)0.672
AA41(16.7)86 (13.7)1.23(0.78–1.94)0.375
AA+AG147/99364/2631.12(0.82–1.52)0.487
A allele1.11(0.89–1.38)0.363

Abbreviations: OR, odds ratio; CI, confidence interval; ADC, adenocarcinoma; SQC, squamous cell carcinoma.

The observed genotype frequency among the control subjects was in agreement with the Hardy–Weinberg equilibrium (P = 0.361).

ORs and their corresponding 95% CIs were calculated by multivariate logistic regression after adjusting for age, sex and smoking status.

Abbreviations: OR, odds ratio; CI, confidence interval; ADC, adenocarcinoma; SQC, squamous cell carcinoma. The observed genotype frequency among the control subjects was in agreement with the Hardy–Weinberg equilibrium (P = 0.361). ORs and their corresponding 95% CIs were calculated by multivariate logistic regression after adjusting for age, sex and smoking status. The association between the TERT rs2736098 polymorphism and NSCLC risk was further examined by stratifying the subjects according to tumor histology. When analyzed according to the histological type, the effect of the TERT rs2736098 polymorphism on the NSCLC risk was significant for adenocarcinomas (A vs. G: OR = 1.28, 95% CI = 1.05–1.57, P = 0.016; AA vs. GG: OR = 1.67, 95% CI = 1.12–2.50, P = 0.013), but not for squamous cell carcinomas (A vs. G: OR = 1.11, 95% CI = 0.89–1.38, P = 0.363; AA vs. GG: OR = 1.23, 95% CI = 0.78–1.94, P = 0.375; AA+AG vs. GG: OR = 1.12, 95% CI = 0.82–1.52, P = 0.487) ( Table 2).

Results of the meta-analysis

Study characteristics

Figure S1 presents the literature search and study selection procedures. Eleven articles [16]–[26] on 12 case-control studies plus the present study, encompassing a total of 10,044 cancer cases and 12,480 controls, were finally included in this meta-analysis. These 13 studies included 3 lung cancer studies, 2 bladder cancer studies, 2 hepatocellular carcinoma (HCC) studies, and 6 other cancer studies (including breast cancer and cervical cancer, among others). There were 5 population-based studies and 8 hospital-based studies. Four studies were conducted in European descendants, and 9 studies were conducted in Asian descendants. The genotype distributions in the controls of all studies were in agreement with HWE, with the exception of 2 studies (P<0.05) [21], [24], which were further tested in the sensitivity analyses. Table 3 presents the characteristics of the included studies.
Table 3

Characteristics of the studies included in the meta-analysis.

First authorPublished yearCountryEthnicityCancer typeControl sourceGenotyping methodCasesControls P of HWE
AAAGGGAAAGGG
Savage [17] 2007PolandCaucasianBreast cancerPBTaqMan97699117114181113130.294
Choi [16] 2009KoreaAsianLung cancerHBPCR87322311553203450.102
Liu [18] 2010USACaucasianSCCHNHBTaqMan72419588784615760.271
Chen [19] 2011ChinaAsianGliomaHBPCR1414613511174864300.246
Ding [20] 2011ChinaAsianHCCHBTaqMan2105635001986045260.255
Gago-Dominguez [21] 2011USACaucasianBladder cancerPBTaqMan43189217432102780.706
Gago-Dominguez [21] 2011ChinaAsianBladder cancerPBTaqMan85236178542702030.009
Wang [22] 2012ChinaAsianCervical cancerPBTaqMan1744443751384803970.710
Hofer [23] 2012AustriaCaucasianColorectal cancerPBTaqMan645861196239630.186
Zhang [24] 2013ChinaAsianHCCHBPCR61206133651581770.004
Li [25] 2013ChinaAsianLung cancerHBTaqMan88207173672502270.886
Sheng [26] 2013ChinaAsianALLHBTaqMan93238236962982760.286
Present study2013ChinaAsianLung cancerHBTaqMan102232205862782630.361

Abbreviations: SCCHN, squamous cell carcinoma of the head and neck; HCC, hepatocellular carcinoma; ALL, acute lymphoblastic leukemia; PB, population based; HB, hospital based; HWE, Hardy-Weinberg equilibrium.

Abbreviations: SCCHN, squamous cell carcinoma of the head and neck; HCC, hepatocellular carcinoma; ALL, acute lymphoblastic leukemia; PB, population based; HB, hospital based; HWE, Hardy-Weinberg equilibrium.

Main meta-analysis results

Overall, as shown in Table 4, a borderline significant association was observed between the TERT rs2736098 polymorphism and overall cancer risk in the homozygote comparison (AA vs. GG: OR = 1.25, 95% CI = 1.07–1.46), recessive genetic model (AA vs. AG+GG: OR = 1.22, 95% CI = 1.06–1.41) and additive genetic model (2*AA+AG vs. 2*GG+AG: OR = 1.10, 95% CI = 1.02–1.18) (Figure 1 and Figure 2), but no statistically significant association was found in the heterozygote comparison (AG vs. GG: OR = 1.02, 95% CI = 0.97–1.08) or the dominant genetic model (AA+AG vs. GG: OR = 1.08, 95% CI = 0.99–1.18).
Table 4

Meta-analysis of the rs2736098 polymorphism in association with cancer risk.

VariablesNAA vs. GGAG vs. GGDominantRecessiveAdditive
(AA+AG vs. GG)(AA vs. AG+GG)(2*AA+AG vs. 2*GG+AG)
OR(95%CI) Phet I2 OR(95%CI) Phet I2 OR(95%CI) Phet I2 OR(95%CI) Phet I2 OR(95%CI) Phet I2
Total13 1.25(1.07–1.46) 0.00163.01.02(0.97–1.08)0.05641.81.08(0.99–1.18)0.01054.3 1.22(1.06–1.41) 0.00261.3 1.10(1.02–1.18) 0.00164.8
Cancer type
 Lung cancer3 1.65(1.34–2.04) 0.8290.01.09(0.95–1.26)0.9690.0 1.20(1.05–1.37) 0.9760.0 1.58(1.30–1.92) 0.8410.0 1.24(1.12–1.36) 0.9360.0
HCC21.15(0.94–1.40)0.6420.01.12(0.97–1.30)0.00190.31.25(0.80–1.94)0.00786.41.08(0.89–1.30)0.3790.01.11(0.94–1.31)0.14752.5
Bladder cancer2 1.55(1.11–2.15) 0.27516.11.07(0.89–1.29)0.4480.01.15(0.96–1.38)0.8310.0 1.50(1.01–2.22) 0.16947.1 1.19(1.04–1.35) 0.5980.0
 Other cancers61.05(0.82–1.35)0.00669.70.97(0.90–1.05)0.3697.40.99(0.89–1.10)0.07849.51.07(0.86–1.33)0.01365.21.01(0.90–1.12)0.00570.0
Ethnicity
Caucasian40.88(0.69–1.13)0.20834.00.95(0.87–1.05)0.34110.40.94(0.83–1.06)0.20534.50.89(0.72–1.10)0.30716.90.95(0.85–1.06)0.13645.8
Asian9 1.39(1.23–1.57) 0.25720.91.07(0.99–1.15)0.08742.1 1.14(1.05–1.24) 0.20726.7 1.34(1.19–1.52) 0.13235.8 1.15(1.09–1.21) 0.3944.9
Source of control
PB51.12(0.78–1.61)0.00276.90.98(0.90–1.07)0.6420.01.01(0.90–1.13)0.20332.81.13(0.80–1.60)0.00177.51.04(0.91–1.19)0.00771.8
HB8 1.31(1.12–1.54) 0.07146.41.05(0.98–1.14)0.01958.3 1.13(1.00–1.26) 0.01559.9 1.26(1.09–1.45) 0.08843.6 1.13(1.04–1.22) 0.02057.8
Publication bias
Begg's test P = 0.583 P = 0.246 P = 0.200 P = 0.855 P = 0.300
Egger's test P = 0.795 P = 0.220 P = 0.123 P = 0.913 P = 0.290

P: test for heterogeneity; OR: odds ratio; CI: confidence interval; N: number of comparisons.

The figures given in bold indicate statistically significant values.

Figure 1

Forest plot of cancer risk associated with the rs2736098 polymorphism (additive model).

The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the study-specific weight (inverse of the variance). The diamonds represent the summary OR and 95% CI. The rs2736098 polymorphism was weakly associated with an increased risk of cancer in the additive model.

Figure 2

Forest plot of cancer risk associated with the rs2736098 polymorphism (AA vs. GG).

The rs2736098 polymorphism was associated with an increased risk of cancer in the homozygote comparison (AA vs. GG).

Forest plot of cancer risk associated with the rs2736098 polymorphism (additive model).

The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the study-specific weight (inverse of the variance). The diamonds represent the summary OR and 95% CI. The rs2736098 polymorphism was weakly associated with an increased risk of cancer in the additive model.

Forest plot of cancer risk associated with the rs2736098 polymorphism (AA vs. GG).

The rs2736098 polymorphism was associated with an increased risk of cancer in the homozygote comparison (AA vs. GG). P: test for heterogeneity; OR: odds ratio; CI: confidence interval; N: number of comparisons. The figures given in bold indicate statistically significant values. In the subgroup analysis according to cancer type, significantly increased risk was observed in lung cancer (AA vs. GG: OR = 1.65, 95% CI = 1.34–2.04; dominant model: OR = 1.20, 95% CI = 1.05–1.37; recessive model: OR = 1.58, 95% CI = 1.30–1.92; additive model: OR = 1.24, 95% CI = 1.12–1.36) and bladder cancer (AA vs. GG: OR = 1.55, 95% CI = 1.11–2.15; recessive model: OR = 1.50, 95% CI = 1.01–2.22; additive model: OR = 1.19, 95% CI = 1.04–1.35). However, no evidence of association was observed in any genetic model between the TERT rs2736098 polymorphism and the risk of HCC or other cancers. When stratified by ethnicity, significantly increased risk was observed in the Asian population (AA vs.GG: OR = 1.39, 95% CI = 1.23–1.57; dominant model: OR = 1.14, 95% CI = 1.05–1.24; recessive model: OR = 1.34, 95% CI = 1.19–1.52; additive model: OR = 1.15, 95% CI = 1.09–1.21) in all genetic models tested, with the exception of the heterozygote comparison (AG vs. GG: OR = 1.07, 95% CI = 0.99–1.15). Nevertheless, no significant association was observed in the European population. In the subgroup analysis by the source of controls, significantly increased risk was observed in hospital-based studies (AA vs. GG: OR = 1.31, 95% CI = 1.12–1.54; dominant model: OR = 1.13, 95% CI = 1.00–1.26; recessive model: OR = 1.26, 95% CI = 1.09–1.45; additive model: OR = 1.13, 95% CI = 1.04–1.22) but was not observed in population-based studies. The main results of this meta-analysis and the heterogeneity test are presented in Table 4.

Test of heterogeneity

For the overall comparisons, significant heterogeneity was observed in four genetic models (AA vs. GG: P . = 0.001, I 2 = 63.0%; AA+AG vs. GG: P = 0.010, I 2 = 54.3%; AA vs. AG+GG: P . = 0.002, I 2 = 61.3%; 2*AA+AG vs. 2*GG+AG: P . = 0.001, I 2 = 64.8%). However, the heterogeneity decreased markedly after stratification, especially in the subgroups of lung cancer (AA vs.GG: P . = 0.829, I 2 = 0.0%; AG vs.GG: P . = 0.969, I 2 = 0.0%; dominant model: P . = 0.976, I 2 = 0.0%; recessive model: P = 0.841, I 2 = 0.0%; additive model: P . = 0.936, I 2 = 0.0%) and bladder cancer (AA vs.GG: P = 0.275, I 2 = 16.1%; AG vs.GG: P . = 0.448, I 2 = 0.0%; dominant model: P . = 0.831, I 2 = 0.0%; recessive model: P . = 0.169, I 2 = 47.1%; additive model: P = 0.598, I 2 = 0.0%). When stratified by ethnicity, heterogeneity was not observed in the subgroups of Asian and European populations (P>0.05 in all genetic comparisons) (Table 4).

Sensitivity analysis

In the sensitivity analyses, the influence of each study on the pooled OR was checked individually by repeating the meta-analysis while omitting each study. Although the genotype distributions of the control groups in the studies by Gago-Dominguez et al. [21] and Zhang et al. [24] did not follow Hardy–Weinberg equilibrium, the corresponding pooled OR and between-study heterogeneity were not significant altered with or without these two studies. Sensitivity analyses indicated that the two independent studies by Savage et al. [17] and Liu et al. [18] were the main origin of the heterogeneity in the overall comparisons (Figure 3). The heterogeneity was effectively decreased or removed after exclusion of these two studies (AA vs. GG: OR = 1.35, 95%CI = 1.22–1.50, P . = 0.158, I 2 = 30.3%; dominant model: OR = 1.12, 95%CI = 1.05–1.20, P . = 0.119, I 2 = 35.0%; additive model: OR = 1.14, 95%CI = 1.09–1.19, P . = 0.142, I 2 = 32.1%). Furthermore, none of the pooled ORs was significantly affected by any single study, suggesting that the results of this meta-analysis were relatively stable.
Figure 3

Sensitivity analysis of the summary OR on the association between the rs2736098 polymorphism and cancer risk under the additive model.

The results were computed by omitting each study (left column) in turn. Meta-analysis random-effect estimates were used. Bars, 95% CI.

Sensitivity analysis of the summary OR on the association between the rs2736098 polymorphism and cancer risk under the additive model.

The results were computed by omitting each study (left column) in turn. Meta-analysis random-effect estimates were used. Bars, 95% CI.

Publication bias assessment

Begg's funnel plot and Egger's test were conducted to assess the publication bias of the literatures. As shown in Figure 4, Figure S2 and Figure S3, the shapes of the funnel plots did not reveal any evidence of an obvious asymmetry in any comparison model. Moreover, Egger's test further provided statistical evidence of funnel plot symmetry (P = 0.795 for AA vs. GG; P = 0.220 for AG vs. GG; P = 0.123 for dominant model; P = 0.913 for recessive model and P = 0.290 for additive model) (Table 4). The results did not indicate any evidence of publication bias.
Figure 4

Begg's funnel plot for publication bias (additive model).

Each point represents a separate study for the indicated association. Log[or], natural logarithm of the odds ratio. Horizontal line, mean effect size.

Begg's funnel plot for publication bias (additive model).

Each point represents a separate study for the indicated association. Log[or], natural logarithm of the odds ratio. Horizontal line, mean effect size.

Discussion

In this study, we examined the association of the TERT rs2736098 polymorphism with the risk for NSCLC in a Chinese Han population. Furthermore, to derive a more precise estimation of the association between this polymorphism and cancer risk, a meta-analysis based on previously published studies and our case-control study was also performed. Our multivariate logistic regression model demonstrated that individuals carrying the A allele or AA genotype exhibited a significantly elevated risk of NSCLC compared with those carrying the G allele or GG genotypes after adjusting for age, gender and smoking status. In the subgroup analysis by histological type, increased cancer risk was observed in adenocarcinomas but not squamous cell carcinomas under the homozygote comparison and the additive genetic model. In addition, the TERT rs2736098 variant A allele showed a marginally significant association with overall cancer risk. The TERT rs2736098 polymorphism is mapped to a region of chromosome 5p15.33. The chromosome 5p15.33 locus contains two well-known genes, telomerase reverse transcriptase (TERT) and cleft lip and palate trans-membrane 1-like (CLPTM1L), which have been implicated in carcinogenesis. Telomerase is expressed in most tumors from virtually all types of cancers, including those of the lung. Telomerase is a relatively specific cancer target, as normal body cells express little or no telomerase for most of their lifespan [11]. Telomere dysfunction in tumor initiation accounts for many aspects of chromosomal instability in human cancers [35]. Cancer cells have been shown to depend on two telomere maintenance mechanisms to gain unlimited proliferation capacity. Generally, telomerase activity is the main mechanism for telomere maintenance. However, 10%–20% of human tumors activate alternative mechanisms of telomere lengthening [36]. The gain at chromosomal region 5p15.33, containing TERT, is one of the most frequent genetic events in early stages of non-small-cell lung cancer [37]. Moreover, it has been reported that telomere length may be associated with the risk of lung cancer [38]–[40]. Little is known about the underlying biological mechanism or functional significance of this polymorphism. Although rs2736098 is a synonymous polymorphism, this TERT SNP has been shown to be associated with telomere length [15]. Many studies have investigated the role of this polymorphism in the etiology of cancer of various organs, including the bladder, liver, and breast, among others. However, the results of related published case-control studies remain inconsistent [16]–[27].For example, Zhang et al. [24] found that the rs2736098 [A] allele contributed significantly to HCC risk. However, Ding et al. [20] detected no association between the TERT rs2736098 polymorphism at 5p15.33 and the risk of HCC. In two population-based case-control studies conducted separately among non-Hispanic whites (NHW) and Asian populations, the TERT rs2736098 polymorphism exhibited a significant association with bladder cancer risk among non-Hispanic whites. However, an association of similar magnitude was not observed in the Asian population [21]. In a Polish study of 1,995 breast cancer cases and 2,296 controls, Savage et al. [17] found no evidence that the TERT rs2736098 polymorphism at 5p15.33 was associated with breast cancer risk. However, in stratified analysis, this variant exhibited evidence of being associated with a reduced risk of breast cancer among individuals with a family history of breast cancer. Although it is difficult to explain the controversial results in these studies, different genetic backgrounds, cancer types and study designs may contribute to the discrepancies. Interestingly, our case-control study demonstrated that the AA homozygote in TERT rs2736098 exhibited a significantly increased risk of developing NSCLC (OR = 1.48, 95% CI = 1.05–2.09, P = 0.025), especially adenocarcinoma (OR = 1.67, 95% CI = 1.12–2.50, P = 0.013), compared with those who carry the GG genotype. The homozygous AA alleles may be correlated with increased lung adenocarcinoma susceptibility. The results of our case-control study support 5p15.33 (TERT-CLPTM1L) as a susceptibility region for lung cancer in the Chinese population [41], [42]. More recently, a Chinese female population study of 501 cancer cases and 576 cancer-free controls also found that the variant allele of rs2736098 was significantly associated with an increased risk of lung cancer, especially in lung adenocarcinomas [25]. Although the underlying biological mechanisms remain largely unknown, differential expression of TERT has been observed between adenocarcinoma and other histological carcinomas of lung cancer [43]–[45]. In the current meta-analysis, a borderline significant association between this polymorphism and cancer risk was observed in the overall analysis, with obvious between-study heterogeneity. However, when stratified by tumor sites, the subgroups of lung cancer and bladder cancer failed to exhibit heterogeneity, suggesting that different tumor sites might be a potential source of heterogeneity. Similarly, after stratifying by ethnicity, heterogeneity was largely reduced in both Asian and European populations, suggesting that ethnicity could partly explain the heterogeneity. Therefore, it may be presumed that the heterogeneity exists mainly owing to differences of ethnicity and tumor types. Furthermore, in the subgroup analysis by ethnicity, we found that individuals carrying the A allele or AA and AA/AG genotypes of the TERT rs2736098 polymorphism were more likely to exhibit an increased cancer risk among Asians but not among Europeans, possibly because of the differences in genetic backgrounds among different populations. Another plausible hypothesis suggests that the TERT rs2736098 polymorphism, a synonymous single nucleotide polymorphism, is only a marker SNP of other functional variants in TERT or other nearby genes. However, this hypothesis remains to be tested. In addition, different study designs and inadequate adjustments for confounding factors might explain, to some extent, the inconsistent results in different cancer types and different populations. The evaluation of heterogeneity, influence analysis, and publication bias confirmed the reliability of the meta-analysis. Some limitations should be addressed in interpreting the results of our case-control study and meta-analysis. First, the sample size of our case-control study was relatively small. Therefore, well-designed population-based studies with large sample sizes and detailed exposure information are needed to further confirm our findings. Additionally, the meta-analysis was based on unadjusted estimates. A more precise analysis should be conducted if more detailed individual data are available, which will allow for an adjusted estimate. Further, in the subgroup analysis stratified by cancer type, the number of studies and subjects analyzed was small, and caution should be taken in interpreting these results. It might be difficult to make a concrete conclusion because few studies were included in the subgroups. Despite these limitations, our meta-analysis also had some advantages. First, significant data were extracted from the related published case-control studies. Second, all studies included in this meta-analysis were case-control investigations and contained available genotype frequencies, which met our inclusion criteria very well. In conclusion, we found that the TERT rs2736098 polymorphism identified in the 5p15.33 region in Caucasians may also predispose to lung cancer, especially adenocarcinomas, in the Chinese population. Moreover, meta-analysis by tumor type suggested that this genetic variant may modify individual susceptibility to lung and bladder cancer. Further studies are required to validate these findings and explain the inconsistent results in different ethnicities and cancer types. PRISMA checklist. (DOC) Click here for additional data file. Flow diagram of the study selection procedure. (TIF) Click here for additional data file. Begg's funnel plot for publication bias (AA vs. GG). (TIF) Click here for additional data file. Begg's funnel plot for publication bias (recessive model). (TIF) Click here for additional data file.
  45 in total

1.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

2.  Avoidable cancer deaths globally.

Authors:  Otis W Brawley
Journal:  CA Cancer J Clin       Date:  2011-02-04       Impact factor: 508.702

Review 3.  Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins.

Authors:  Paula Martínez; María A Blasco
Journal:  Nat Rev Cancer       Date:  2011-03       Impact factor: 60.716

Review 4.  The role of telomeres in stem cells and cancer.

Authors:  Cagatay Günes; K Lenhard Rudolph
Journal:  Cell       Date:  2013-01-31       Impact factor: 41.582

5.  Operating characteristics of a rank correlation test for publication bias.

Authors:  C B Begg; M Mazumdar
Journal:  Biometrics       Date:  1994-12       Impact factor: 2.571

6.  The 5p15.33 locus is associated with risk of lung adenocarcinoma in never-smoking females in Asia.

Authors:  Chao Agnes Hsiung; Qing Lan; Yun-Chul Hong; Chien-Jen Chen; H Dean Hosgood; I-Shou Chang; Nilanjan Chatterjee; Paul Brennan; Chen Wu; Wei Zheng; Gee-Chen Chang; Tangchun Wu; Jae Yong Park; Chin-Fu Hsiao; Yeul Hong Kim; Hongbing Shen; Adeline Seow; Meredith Yeager; Ying-Huang Tsai; Young Tae Kim; Wong-Ho Chow; Huan Guo; Wen-Chang Wang; Sook Whan Sung; Zhibin Hu; Kuan-Yu Chen; Joo Hyun Kim; Ying Chen; Liming Huang; Kyoung-Mu Lee; Yen-Li Lo; Yu-Tang Gao; Jin Hee Kim; Li Liu; Ming-Shyan Huang; Tae Hoon Jung; Guangfu Jin; Neil Caporaso; Dianke Yu; Chang Ho Kim; Wu-Chou Su; Xiao-Ou Shu; Ping Xu; In-San Kim; Yuh-Min Chen; Hongxia Ma; Min Shen; Sung Ick Cha; Wen Tan; Chin-Hao Chang; Jae Sook Sung; Mingfeng Zhang; Tsung-Ying Yang; Kyong Hwa Park; Jeff Yuenger; Chih-Liang Wang; Jeong-Seon Ryu; Yongbing Xiang; Qifei Deng; Amy Hutchinson; Jun Suk Kim; Qiuyin Cai; Maria Teresa Landi; Chong-Jen Yu; Ju-Yeon Park; Margaret Tucker; Jen-Yu Hung; Chien-Chung Lin; Reury-Perng Perng; Paolo Boffetta; Chih-Yi Chen; Kun-Chieh Chen; Shi-Yi Yang; Chi-Yuan Hu; Chung-Kai Chang; Joseph F Fraumeni; Stephen Chanock; Pan-Chyr Yang; Nathaniel Rothman; Dongxin Lin
Journal:  PLoS Genet       Date:  2010-08-05       Impact factor: 5.917

7.  hTERT rs2736098 genetic variants and susceptibility of hepatocellular carcinoma in the Chinese population: a case-control study.

Authors:  Chao Zhang; Ya-Ping Tian; Yue Wang; Feng-Hua Guo; Jun-Fang Qin; Hong Ni
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2013-02

8.  Common genetic variants on 5p15.33 contribute to risk of lung adenocarcinoma in a Chinese population.

Authors:  Guangfu Jin; Lin Xu; Yongqian Shu; Tian Tian; Jie Liang; Yan Xu; Furu Wang; Jianjian Chen; Juncheng Dai; Zhibin Hu; Hongbing Shen
Journal:  Carcinogenesis       Date:  2009-04-15       Impact factor: 4.944

9.  Significant association of 5p15.33 (TERT-CLPTM1L genes) with lung cancer in Chinese Han population.

Authors:  Zhenhong Zhao; Cong Li; Lixin Yang; Xiaobo Zhang; Xueying Zhao; Xiao Song; Xiaoying Li; Jiucun Wang; Ji Qian; Yajun Yang; Li Jin; Hongyan Chen; Daru Lu
Journal:  Exp Lung Res       Date:  2013-01-31       Impact factor: 2.459

Review 10.  Telomerase and cancer therapeutics.

Authors:  Calvin B Harley
Journal:  Nat Rev Cancer       Date:  2008-03       Impact factor: 60.716

View more
  18 in total

1.  Platelet VEGF and serum TGF-β1 levels predict chemotherapy response in non-small cell lung cancer patients.

Authors:  Bao-Hong Fu; Zhan-Zhao Fu; Wei Meng; Tao Gu; Xiao-Dong Sun; Zhi Zhang
Journal:  Tumour Biol       Date:  2015-03-29

2.  Case-Control Study on Impact of the Telomerase Reverse Transcriptase Gene Polymorphism and Additional Single Nucleotide Polymorphism (SNP)- SNP Interaction on Non-Small Cell Lung Cancers Risk in Chinese Han Population.

Authors:  Yan-Li Xing; Feng Liu; Jian-Feng Li; Jian-Cong Lin; Guo-Dong Zhu; Ming Li; Chang-Ran Zhang; Yuan-Yuan Niu
Journal:  J Clin Lab Anal       Date:  2016-05-07       Impact factor: 2.352

Review 3.  Synonymous Variants: Necessary Nuance in Our Understanding of Cancer Drivers and Treatment Outcomes.

Authors:  Nayiri M Kaissarian; Douglas Meyer; Chava Kimchi-Sarfaty
Journal:  J Natl Cancer Inst       Date:  2022-08-08       Impact factor: 11.816

4.  Elevated matrix metalloproteinase-7 expression promotes metastasis in human lung carcinoma.

Authors:  Ji-Chang Han; Xian-Dong Li; Jin Du; Feng Xu; Yu-Ju Wei; Hong-Bing Li; Yi-Jie Zhang
Journal:  World J Surg Oncol       Date:  2015-01-14       Impact factor: 2.754

5.  TERT Polymorphism rs2853669 Influences on Lung Cancer Risk in the Korean Population.

Authors:  Seung Soo Yoo; Sook Kyung Do; Jin Eun Choi; Shin Yup Lee; Jaehee Lee; Seung Ick Cha; Chang Ho Kim; Jae Yong Park
Journal:  J Korean Med Sci       Date:  2015-09-12       Impact factor: 2.153

6.  Association between the TERT Genetic Polymorphism rs2853676 and Cancer Risk: Meta-Analysis of 76,108 Cases and 134,215 Controls.

Authors:  Jin-Lin Cao; Ping Yuan; Abudumailamu Abuduwufuer; Wang Lv; Yun-Hai Yang; Jian Hu
Journal:  PLoS One       Date:  2015-06-04       Impact factor: 3.240

7.  TERT Gene rs2736100 and rs2736098 Polymorphisms are Associated with Increased Cancer Risk: A Meta-Analysis.

Authors:  Xinyu Zhang; Yan Chen; Donglin Yan; Jing Han; Longbiao Zhu
Journal:  Biochem Genet       Date:  2021-06-28       Impact factor: 1.890

8.  Increased risk of developing lung cancer in Asian patients carrying the TERT rs2736098 G>A polymorphism: evidence from 3,354 cases and 3,518 controls.

Authors:  Zhenhua Yang; Xunlei Zhang; Surong Fang; Yan Tan; Haijun Yan; Wei Gu; Jianhong Wang
Journal:  Onco Targets Ther       Date:  2015-09-30       Impact factor: 4.147

9.  Effects of CYP3A5 genetic polymorphism and smoking on the prognosis of non-small-cell lung cancer.

Authors:  Li-Peng Jiang; Zhi-Tu Zhu; Chun-Yan He
Journal:  Onco Targets Ther       Date:  2016-03-14       Impact factor: 4.147

Review 10.  Human Specific Regulation of the Telomerase Reverse Transcriptase Gene.

Authors:  Fan Zhang; De Cheng; Shuwen Wang; Jiyue Zhu
Journal:  Genes (Basel)       Date:  2016-06-28       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.